+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dexcel PT Israel Ltd - Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 24 Pages
  • February 2025
  • Region: Israel
  • GlobalData
  • Dexcel Pharma
  • ID: 4076490
Dexcel PT Israel Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Dexcel PT Israel Ltd (Dexcel Pharma) develops, manufactures and markets branded and generic pharmaceuticals in various dosage forms. The company's major products include PerioChip (chlorhexidine gluconate), a non-antibiotic adjunct treatment for scaling and root planning and adult periodontitis; Deximune, an immunosuppressant; and omeprazole delayed released tablet for the treatment of gastroesophageal reflux disease, peptic ulcer disease, and Zollinger-Ellison syndrome. It also offers products for cardiovascular disorders, dental diseases, allergies, pain relief, and skin diseases, among others. The company develops formulations using proprietary, patent-protected, drug delivery technologies. It sells its products through a network of subsidiaries and distributors in Western Europe. Dexcel Pharma is headquartered in Or Akiva, Haifa, Israel.

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Dexcel PT Israel Ltd - Key Facts
  • Dexcel PT Israel Ltd - Key Employees
  • Dexcel PT Israel Ltd - Major Products and Services
  • Dexcel PT Israel Ltd - History
  • Dexcel PT Israel Ltd - Company Statement
  • Dexcel PT Israel Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Dexcel PT Israel Ltd - Business Description
  • Dexcel PT Israel Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Dexcel PT Israel Ltd - Strengths
  • Dexcel PT Israel Ltd - Weaknesses
  • Dexcel PT Israel Ltd - Opportunities
  • Dexcel PT Israel Ltd - Threats
  • Dexcel PT Israel Ltd - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Dexcel PT Israel Ltd, Recent Deals Summary
Section 4 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Dexcel PT Israel Ltd, Key Facts
  • Dexcel PT Israel Ltd, Key Employees
  • Dexcel PT Israel Ltd, Major Products and Services
  • Dexcel PT Israel Ltd, History
  • Dexcel PT Israel Ltd, Other Locations
  • Dexcel PT Israel Ltd, Subsidiaries
  • Dexcel PT Israel Ltd, Key Competitors
  • Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Dexcel PT Israel Ltd, Recent Deals Summary
List of Figures
  • Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Dexcel PT Israel Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • PainReform Ltd
  • Teva Pharmaceutical Industries Ltd
  • BiomX Inc
  • Kamada Pharmaceuticals
  • Rafa Laboratories Co Ltd